Journal Mobile Options
Table of Contents
Vol. 26, No. 3, 2006
Issue release date: April 2006
Neuroepidemiology 2006;26:140–146

The Relation of Cigarette Smoking to Incident Alzheimer’s Disease in a Biracial Urban Community Population

Aggarwal N.T. · Bienias J.L. · Bennett D.A. · Wilson R.S. · Morris M.C. · Schneider J.A. · Shah R.C. · Evans D.A.
aRush Alzheimer’s Disease Center; bRush Institute for Healthy Aging; cDepartment of Neurological Sciences; dInternal Medicine; ePreventive Medicine; fPsychology; gFamily Medicine, Rush University Medical Center, Chicago, Ill., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The relationship between smoking status and incident Alzheimer’s disease (AD) was investigated in a random stratified sample of a biracial community in Chicago. Analyses are based on 1,064 persons (of 1,134 evaluated) who had data on smoking status, disease incidence, and key covariates such as apolipoprotein allele status. During a mean of about 4 years of follow-up, 170 persons met criteria for incident AD. Current smoking was associated with increased risk of incident AD (OR = 3.4, 95% CI = 1.4–8.0) compared to persons who never smoked. There was no apparent increase in risk of AD for former smokers compared to persons who never smoked (OR = 0.9, 95% CI = 0.5–1.7). Apolipoprotein E allele status modified this association in that former smokers with a υ4 allele were less likely to develop AD (p = 0.04) than those who never smoked. Former smokers also appeared to have a reduced risk of developing AD as their pack-years of smoking increased (p = 0.02)such that the odds of developing AD increased by 50% for every 10 years of smoking cessation (OR = 1.3, CI = 0.9–1.7). The results suggest that older people who currently smoke are more likely to develop AD compared to those who never smoked; the relation between those who used to smoke but quit and the risk of AD is complex and requires further research.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Peterson GM: Epidemiology, screening and prevention of lung cancer. Curr Opin Oncol 1994;6:156–161.
  2. Davila DG, Williams DE: The etiology of lung cancer. Mayo Clin Proc 1993;68:170–182.
  3. Shinton R, Beevers G: Meta-analysis of the relation between cigarette smoking and stroke. BMJ 1989;298:89–94.
  4. Higa M, Davanipour Z: Smoking and stroke. Neuroepidemiology 1991;10:211–222.
  5. Colditz GA: Cigarette smoking and coronary artery disease; in Diana JN (ed): Tobacco Smoking and Atherosclerosis. New York, Plenum Press, 1990, pp 311–321.
  6. Doll R: Tobacco: an overview of health effects. IACR Sci Publ 1986;74:11–22.

    External Resources

  7. Van Duijn CM, Hofman A: Relation between nicotine intake and Alzheimer’s disease. BMJ 1991;302:491–494.
  8. Brenner DE, Kukull WA, van Belle G, et al: Relationship between cigarette smoking and Alzheimer’s disease in a population-based case-control study. Neurology 1993;43:293–300.
  9. Graves AB, van Duijn CM, Chandra V, et al: Alcohol and tobacco consumption as risk factors for Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20:S48–S57.
  10. Doll R, Peto R, Boreham J, et al: Smoking and dementia in male British doctors: prospective study. BMJ 2000;320:1097–1102.
  11. Hebert LE, Scherr PA, Beckett LA, et al: Relation of smoking and alcohol consumption to incident Alzheimer’s disease. Am J Epidemiol 1992;135:347–355.
  12. Broe GA, Creasey H, Jorm AF, Bennett HP, Casey B, Waite LM, Grayson DA, Cullen J: Health habits and risk of cognitive impairment and dementia in old age: a prospective study on the effects of exercise, smoking and alcohol consumption. Aust NZ J Public Health 1998;22:621–623.
  13. Wang HX, Fratiglioni L, Frisoni BG, et al: Smoking and the occurrence of Alzheimer’s disease: cross-sectional and longitudinal data in a population-based study. Am J Epidemiol 1999;1149:640–644.

    External Resources

  14. Ott A, Slooter AJ, Hofman A, et al: Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam study. Lancet 1998;351:1840–1843.
  15. Merchant C, Tang MX, Albert S, et al: The influence of smoking on the risk of Alzheimer’s disease. Neurology 1999;52:1408–1412.
  16. Galanis DJ, Petrovitch H, Launer LJ, et al: Smoking history in middle age and subsequent cognitive performance in elderly Japanese-American men – the Honolulu-Asia Study. Am J Epidemiol 1997;145:507–515.
  17. Launer LJ, Andersen L, Dewey ME, et al: Rates and risk factors for dementia and Alzheimer’s disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999;52:78–84.
  18. Ott A, Andersen K, Dewey ME, et al: Effect of smoking on global cognitive function in non-demented elderly. Neurology 2004;62:920–924.
  19. Evans DA, Bennett DA, Wilson RS, et al: Incidence of Alzheimer’s disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003;50:185–189.
  20. Wilson RS, Bennett DA, Bienias JL, et al: Cognitive activity and incident AD in a population-based sample of older persons. Neurology 2002;59:1910–1914.
  21. Bienias JL, Beckett LA, Bennett DA, Wilson RS, Evans DA: Design of the Chicago Health and Aging Project. J Alzheimers Dis 2003;5:349–355.

    External Resources

  22. Welsh KA, Butters N, Mohs RC, et al: The CERAD. Part V. A normative study of the neuropsychological battery. Neurology 1994;44:609–614.
  23. Wechsler D: Wechsler Memory Scale – Revised Manual. New York, Psychological Corp, 1987.
  24. Albert MS, Smith LA, Scherr PA, et al: Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer’s disease. Int J Neurosci 1991;57:167–178.
  25. Smith A: Symbol Digit Modalities Test Manual – Revised. Los Angeles, Western Psychological, 1984.
  26. Benton A, Sivan A, Hamsher K, Varney N, Spreen O: Contributions to Neuropsychological Assessment, ed 2. New York, Oxford University Press, 1994.
  27. Goodglass H, Kaplan E: The Assessment of Aphasia and Related Disorders. Philadelphia, Lea & Febiger, 1972.
  28. Ekstrom RB, French JW, Harman HH, Dermen D: Manual for Kit of Factor Referenced Cognitive Test. Princeton, Educational Testing Service, 1976.
  29. Cooper JA, Sagar JH: Incidental and intentional recall in Parkinson’s disease: an account based on diminished attentional resources. J Clin Exp Neuropsycohol 1993;15:713–731.
  30. Raven JC, Court JH, Raven J: Standard Progressive Matrices 1992 edition; Raven Manual Section 3. Oxford, Oxford Psychologist Press, 1992.
  31. Nelson HE: National Adult Reading Test (NART) Test Manual. Windsor/Berks, NFER-Nelson Publ Co, 1982.
  32. Morris MC, Evans DA, Bienias JL, et al: Dietary intake of antioxidant nutrients and the risk of incident Alzheimer’s disease. JAMA 2002;287:3230–3237.
  33. Wilson RS, Mendes de Leon CF, Bennett DA, Bienias JL, Evans DA: Depressive symptoms and cognitive decline in a community population of older persons. J Neurol Neurosurg Psychiatry 2004;75:126–129.
  34. Wilson RS, Bennett DA, Beckett LA, et al: Cognitive activity in older persons from a geographically defined population. Gerontol B Psychol Sci Soc Sci 1999;54:P155–P160.
  35. Wilson RS, Mendes de Leon CF, Barnes LL, et al: Participation in cognitively stimulating activities and risk of incident Alzheimer’s disease. JAMA 2002;287:742–748.
  36. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett L, Aggarwal NT, Barnes LL, Fox JH, Bach J: Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198–205.
  37. McKhann G, Drachmann D, Folstein M, et al: Clinical diagnosis of Alzheimer’s disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  38. Roman GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINCDS-AIREN International Workshop. Neurology 1993;43:250–260.
  39. Hixson JE, Vernier DO: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545–548.
  40. Wenham PR, Price WH, Blundell G: Apolipoprotein E genotyping by one stage PCR. Lancet 1991;337:1158–1159.
  41. Wolter KM: Introduction to Variance Estimation. Berlin, Springer, 1985.
  42. Lee ES, Forthofer RN, Lorimor RJ: Analyzing Complex Survey Data. Sage University Paper Series on Quantitative Applications in the Social Sciences, 07-071. Beverly Hills, Sage Publications, 1989.
  43. Bienias JL: Replicate-based variance estimation in a SAS® Macro. Proc 14th Annual Meeting of the North East SAS Users Group. Statistics, Data Analysis, and Econometrics Section, 2001, pp 727–735.
  44. Bienias JL, Kott PS, Evans DA: Applying the delete-a-group jackknife variance estimator to analyses of data from a complex longitudinal survey. Proc Annual Meeting of the American Statistical Association, Survey Research Methods Section (CD-ROM). Alexandra, American Statistical Association, 2003, pp 539–544.
  45. SAS Institute Inc SAS/STAT® User’s Guide, Version 8. Cary, SAS Institute, 2000.
  46. Tyas SL, White LR, Petrovitch H, et al: Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2003;24:589–596.
  47. Benwell ME, Balfour DJK, Anderson JM: Evidence that tobacco smoking increases the density of (–)-(3H) nicotine binding sties in human brain. J Neurochem 1988;50:1243–1247.
  48. Kihara T, Shimohama S, Urushitani M, et al: Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β-amyloid toxicity. Brain Res 1998;792:331–334.
  49. Schwartz RD, Kellar KJ: Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 1983;220:214–216.
  50. Hellstrom-Lindahl E, Mousavi M, Ravid R, Nordberg A: Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer’s patients. Neurobiol Dis 2004;15:351–360.
  51. Nordberg A, Hellstrom-Lindahl E, Lee M, et al: Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer’s disease. J Neurochem 2002;81:655–658.
  52. Salomon AR, Marcinowski KL, Friedland RP, Zagorski MG: Nicotine inhibits amyloid formation by the β peptide. Biochemistry 1996;35:13568–13578.
  53. Colditz GA, Bonita R, Stampfer MJ, et al: Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med 1988;318:937–941.
  54. Bartecchi CE, MacKenzie TD, Schrier RW: The human costs of tobacco use. N Engl J Med 1994;330:907–912.
  55. Shinton R, Beevers G: Meta-analysis of the relation between cigarette smoking and stroke. Br Med J 1989;298:789–794.
  56. Cruickshank JM, Neil-Dwyer G, Dorrance DE, Hayes Y, Patel S: Acute effects of smoking on blood pressure and cerebral blood flow. J Hum Hypertens 1989;3:443–449.
  57. Higa M, Davanipour Z: Smoking and stroke. Neuroepidemiology 1991;10:211–222.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50